Estrogen receptor ligands. Part 5: The SAR of dihydrobenzoxathiins containing modified basic side chains.

Article Details

Citation

Copy to clipboard

Tan Q, Birzin ET, Chan W, Tien Yang Y, Pai LY, Hayes EC, DaSilva CA, DiNinno F, Rohrer SP, Schaeffer JM, Hammond ML

Estrogen receptor ligands. Part 5: The SAR of dihydrobenzoxathiins containing modified basic side chains.

Bioorg Med Chem Lett. 2004 Jul 16;14(14):3747-51.

PubMed ID

15203155 [ View in PubMed

]

Abstract

Dihydrobenzoxathiin analogs (1-11) with modifications on the basic side chain region were prepared and evaluated for estrogen/anti-estrogen activity in both in vitro and in vivo models. The compounds generally maintained a high degree of selectivity for ERalpha over ERbeta, similar to the original lead compound I. Many of the compounds also maintained high potency in the inhibition of human carcinoma MCF-7 cell growth. However, all were less potent in the inhibition of estradiol-triggered uterine growth. This work demonstrates the sensitive nature of modification to the antagonist basic side chain region.

DrugBank Data that Cites this Article

Binding Properties

Drug	Target	Property	Measurement	pH	Temperature (°C)
Compound 4-D	Estrogen receptor alpha	IC 50 (nM)	0.8	N/A	N/A	Details
Estradiol	Estrogen receptor alpha	IC 50 (nM)	1.3	N/A	N/A	Details
Estradiol	Estrogen receptor beta	IC 50 (nM)	1.1	N/A	N/A	Details